vs
MYOMO, INC.（MYO）与Rocky Mountain Chocolate Factory, Inc.（RMCF）财务数据对比。点击上方公司名可切换其他公司
MYOMO, INC.的季度营收约是Rocky Mountain Chocolate Factory, Inc.的1.5倍（$11.4M vs $7.5M），Rocky Mountain Chocolate Factory, Inc.净利率更高（-2.1% vs -33.6%，领先31.5%），Rocky Mountain Chocolate Factory, Inc.同比增速更快（-4.4% vs -5.9%），Rocky Mountain Chocolate Factory, Inc.自由现金流更多（$-1.3M vs $-2.4M），过去两年MYOMO, INC.的营收复合增速更高（73.9% vs 1.9%）
MYOMO INC.是一家医疗科技企业，研发和生产可穿戴肌电矫形设备，帮助上肢瘫痪或无力的患者恢复肢体活动能力，核心产品面向中风、脊髓损伤及其他神经系统疾病患者，主要市场覆盖北美地区。
落基山巧克力厂是美国知名巧克力企业，同时开展国际特许经营业务，集糖果生产与零售运营于一体，总部位于美国科罗拉多州杜兰戈，除美国本土门店外，在巴拿马、菲律宾也设有经营网点。
MYO vs RMCF — 直观对比
营收规模更大
MYO
是对方的1.5倍
$7.5M
营收增速更快
RMCF
高出1.5%
-5.9%
净利率更高
RMCF
高出31.5%
-33.6%
自由现金流更多
RMCF
多$1.1M
$-2.4M
两年增速更快
MYO
近两年复合增速
1.9%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $11.4M | $7.5M |
| 净利润 | $-3.8M | $-155.0K |
| 毛利率 | 68.6% | 34.0% |
| 营业利润率 | -24.4% | 1.1% |
| 净利率 | -33.6% | -2.1% |
| 营收同比 | -5.9% | -4.4% |
| 净利润同比 | -1366.4% | 81.7% |
| 每股收益（稀释后） | $-0.09 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MYORMCF
| Q4 25 | $11.4M | $7.5M | ||
| Q3 25 | $10.1M | $6.8M | ||
| Q2 25 | $9.7M | $6.4M | ||
| Q1 25 | $9.8M | $8.9M | ||
| Q4 24 | $12.1M | $7.9M | ||
| Q3 24 | $9.2M | $6.4M | ||
| Q2 24 | $7.5M | $6.4M | ||
| Q1 24 | $3.8M | $7.3M |
净利润MYORMCF
| Q4 25 | $-3.8M | $-155.0K | ||
| Q3 25 | $-3.7M | $-662.0K | ||
| Q2 25 | $-4.6M | $-324.0K | ||
| Q1 25 | $-3.5M | $-2.9M | ||
| Q4 24 | $-260.1K | $-847.0K | ||
| Q3 24 | $-966.4K | $-722.0K | ||
| Q2 24 | $-1.1M | $-1.7M | ||
| Q1 24 | $-3.8M | $-1.6M |
毛利率MYORMCF
| Q4 25 | 68.6% | 34.0% | ||
| Q3 25 | 63.8% | 23.6% | ||
| Q2 25 | 62.7% | 31.1% | ||
| Q1 25 | 67.2% | 10.8% | ||
| Q4 24 | 71.4% | 23.4% | ||
| Q3 24 | 75.4% | 31.8% | ||
| Q2 24 | 70.8% | 12.8% | ||
| Q1 24 | 61.2% | 24.3% |
营业利润率MYORMCF
| Q4 25 | -24.4% | 1.1% | ||
| Q3 25 | -34.9% | -7.0% | ||
| Q2 25 | -47.6% | -2.3% | ||
| Q1 25 | -35.8% | -30.3% | ||
| Q4 24 | -2.0% | -8.9% | ||
| Q3 24 | -10.4% | -14.3% | ||
| Q2 24 | -14.8% | -25.4% | ||
| Q1 24 | -103.6% | -21.7% |
净利率MYORMCF
| Q4 25 | -33.6% | -2.1% | ||
| Q3 25 | -36.3% | -9.7% | ||
| Q2 25 | -48.0% | -5.1% | ||
| Q1 25 | -35.2% | -32.5% | ||
| Q4 24 | -2.2% | -10.7% | ||
| Q3 24 | -10.5% | -11.3% | ||
| Q2 24 | -14.9% | -25.9% | ||
| Q1 24 | -102.2% | -21.9% |
每股收益（稀释后）MYORMCF
| Q4 25 | $-0.09 | $-0.02 | ||
| Q3 25 | $-0.09 | $-0.09 | ||
| Q2 25 | $-0.11 | $-0.04 | ||
| Q1 25 | $-0.08 | $-0.38 | ||
| Q4 24 | $0.00 | $-0.11 | ||
| Q3 24 | $-0.03 | $-0.11 | ||
| Q2 24 | $-0.03 | $-0.26 | ||
| Q1 24 | $-0.10 | $-0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $18.4M | $641.0K |
| 总债务越低越好 | $11.2M | — |
| 股东权益账面价值 | $11.4M | $6.0M |
| 总资产 | $38.6M | $20.7M |
| 负债/权益比越低杠杆越低 | 0.98× | — |
8季度趋势，按日历期对齐
现金及短期投资MYORMCF
| Q4 25 | $18.4M | $641.0K | ||
| Q3 25 | $12.6M | $2.0M | ||
| Q2 25 | $15.5M | $893.0K | ||
| Q1 25 | $21.5M | $720.0K | ||
| Q4 24 | $24.9M | $1.1M | ||
| Q3 24 | $6.6M | $973.0K | ||
| Q2 24 | $9.0M | $637.0K | ||
| Q1 24 | $11.0M | $2.1M |
总债务MYORMCF
| Q4 25 | $11.2M | — | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $1.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益MYORMCF
| Q4 25 | $11.4M | $6.0M | ||
| Q3 25 | $14.6M | $6.1M | ||
| Q2 25 | $17.6M | $6.7M | ||
| Q1 25 | $21.7M | $7.0M | ||
| Q4 24 | $24.7M | $9.8M | ||
| Q3 24 | $9.3M | $10.5M | ||
| Q2 24 | $9.7M | $9.0M | ||
| Q1 24 | $10.9M | $10.6M |
总资产MYORMCF
| Q4 25 | $38.6M | $20.7M | ||
| Q3 25 | $34.1M | $22.3M | ||
| Q2 25 | $38.7M | $20.1M | ||
| Q1 25 | $40.9M | $21.2M | ||
| Q4 24 | $42.2M | $21.6M | ||
| Q3 24 | $16.3M | $21.1M | ||
| Q2 24 | $16.2M | $19.0M | ||
| Q1 24 | $16.5M | $20.6M |
负债/权益比MYORMCF
| Q4 25 | 0.98× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | 0.08× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.1M | $-1.2M |
| 自由现金流经营现金流 - 资本支出 | $-2.4M | $-1.3M |
| 自由现金流率自由现金流/营收 | -21.0% | -16.9% |
| 资本支出强度资本支出/营收 | 10.9% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-18.7M | — |
8季度趋势，按日历期对齐
经营现金流MYORMCF
| Q4 25 | $-1.1M | $-1.2M | ||
| Q3 25 | $-1.8M | $-488.0K | ||
| Q2 25 | $-8.9M | $350.0K | ||
| Q1 25 | $-2.7M | $1.2M | ||
| Q4 24 | $3.4M | $-2.1M | ||
| Q3 24 | $-1.5M | $-3.5M | ||
| Q2 24 | $-1.9M | $-2.2M | ||
| Q1 24 | $-3.2M | $129.0K |
自由现金流MYORMCF
| Q4 25 | $-2.4M | $-1.3M | ||
| Q3 25 | $-2.9M | $-544.0K | ||
| Q2 25 | $-10.1M | $182.0K | ||
| Q1 25 | $-3.3M | — | ||
| Q4 24 | $2.5M | — | ||
| Q3 24 | $-1.8M | $-4.6M | ||
| Q2 24 | $-2.0M | $-2.6M | ||
| Q1 24 | $-3.3M | $-352.3K |
自由现金流率MYORMCF
| Q4 25 | -21.0% | -16.9% | ||
| Q3 25 | -28.6% | -8.0% | ||
| Q2 25 | -104.9% | 2.9% | ||
| Q1 25 | -34.0% | — | ||
| Q4 24 | 20.8% | — | ||
| Q3 24 | -19.7% | -72.6% | ||
| Q2 24 | -27.1% | -40.2% | ||
| Q1 24 | -88.0% | -4.9% |
资本支出强度MYORMCF
| Q4 25 | 10.9% | 0.5% | ||
| Q3 25 | 10.4% | 0.8% | ||
| Q2 25 | 13.0% | 2.6% | ||
| Q1 25 | 6.8% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 3.5% | 17.5% | ||
| Q2 24 | 1.6% | 6.5% | ||
| Q1 24 | 1.6% | 6.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MYO
| Direct To Patient | $7.9M | 69% |
| Clinical And Medical Providers | $3.5M | 31% |
RMCF
| Manufacturing | $5.9M | 78% |
| Transferred At Point In Time | $1.2M | 16% |
| Other | $414.0K | 5% |
